Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report issued on Saturday. The brokerage set a “sell” rating on the stock.

MBRX has been the subject of several other reports. Maxim Group dropped their target price on Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, March 26th. Roth Mkm reissued a “buy” rating and set a $40.00 price objective on shares of Moleculin Biotech in a research report on Friday.

Moleculin Biotech Price Performance

NASDAQ MBRX opened at $4.63 on Friday. The company has a market cap of $10.32 million, a P/E ratio of -0.34 and a beta of 1.95. The stock has a 50-day moving average of $7.33 and a two-hundred day moving average of $8.19. Moleculin Biotech has a 1-year low of $4.34 and a 1-year high of $24.75.

Hedge Funds Weigh In On Moleculin Biotech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. purchased a new stake in Moleculin Biotech in the fourth quarter valued at approximately $39,000. Atticus Wealth Management LLC purchased a new stake in Moleculin Biotech in the fourth quarter valued at approximately $43,000. Renaissance Technologies LLC lifted its stake in Moleculin Biotech by 79.3% in the first quarter. Renaissance Technologies LLC now owns 59,900 shares of the company’s stock valued at $107,000 after buying an additional 26,500 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Moleculin Biotech in the fourth quarter valued at approximately $55,000. Finally, State Street Corp lifted its stake in Moleculin Biotech by 19.2% in the first quarter. State Street Corp now owns 71,397 shares of the company’s stock valued at $127,000 after buying an additional 11,497 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.